BR112022018022A2 - Método para tratar doença inflamatória intestinal ii - Google Patents

Método para tratar doença inflamatória intestinal ii

Info

Publication number
BR112022018022A2
BR112022018022A2 BR112022018022A BR112022018022A BR112022018022A2 BR 112022018022 A2 BR112022018022 A2 BR 112022018022A2 BR 112022018022 A BR112022018022 A BR 112022018022A BR 112022018022 A BR112022018022 A BR 112022018022A BR 112022018022 A2 BR112022018022 A2 BR 112022018022A2
Authority
BR
Brazil
Prior art keywords
inflammatory bowel
bowel disease
treat inflammatory
subject
treat
Prior art date
Application number
BR112022018022A
Other languages
English (en)
Portuguese (pt)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900743A external-priority patent/AU2020900743A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022018022A2 publication Critical patent/BR112022018022A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112022018022A 2020-03-11 2021-03-11 Método para tratar doença inflamatória intestinal ii BR112022018022A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020900743A AU2020900743A0 (en) 2020-03-11 Method for treating inflammatory bowel disease II
PCT/EP2021/056193 WO2021180851A1 (en) 2020-03-11 2021-03-11 Method for treating inflammatory bowel disease ii

Publications (1)

Publication Number Publication Date
BR112022018022A2 true BR112022018022A2 (pt) 2022-10-18

Family

ID=74884938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018022A BR112022018022A2 (pt) 2020-03-11 2021-03-11 Método para tratar doença inflamatória intestinal ii

Country Status (9)

Country Link
US (1) US20230104108A1 (enExample)
EP (1) EP4117623A1 (enExample)
JP (1) JP2023517641A (enExample)
KR (1) KR20220152240A (enExample)
CN (1) CN115297875A (enExample)
AU (1) AU2021235055A1 (enExample)
BR (1) BR112022018022A2 (enExample)
CA (1) CA3170918A1 (enExample)
WO (1) WO2021180851A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2021180850A1 (en) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Method for treating inflammatory bowel disease i

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US20070026377A1 (en) * 2000-02-10 2007-02-01 The Regents Of The University Of California Methods for preserving nucleated mammalian cells
US8465733B2 (en) * 2007-11-02 2013-06-18 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
CN104873542A (zh) * 2015-05-21 2015-09-02 北京青藤谷禧干细胞科技研究院有限公司 一种脐带间充质干细胞注射液及其制备方法和应用
EP3419635B1 (en) * 2016-02-22 2022-01-05 Centauri Biotech, S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
WO2018002930A1 (en) * 2016-06-30 2018-01-04 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
WO2018182612A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of stem cells at the site of gastrointestinal tract disease
WO2021180850A1 (en) * 2020-03-11 2021-09-16 Mesoblast International Sàrl Method for treating inflammatory bowel disease i

Also Published As

Publication number Publication date
AU2021235055A1 (en) 2022-09-29
US20230104108A1 (en) 2023-04-06
EP4117623A1 (en) 2023-01-18
WO2021180851A1 (en) 2021-09-16
JP2023517641A (ja) 2023-04-26
KR20220152240A (ko) 2022-11-15
CN115297875A (zh) 2022-11-04
CA3170918A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
BR112022017560A2 (pt) Método para tratar doença inflamatória intestinal i
ES2550059T3 (es) Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
BR112018075734A2 (pt) composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
BR112018068986A2 (pt) composição para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, método para reduzir a expressão de mir-3120 em uma célula ou tecido de um indivíduo, e método para produzir células ips
MX2021007076A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112021020302A2 (pt) Composição, e método de tratamento de um sujeito com câncer
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
EA201490512A1 (ru) Композиции, содержащие культивируемую в анаэробных условиях микробиоту кишечника человека
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
BR112021021676A2 (pt) Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal
Robinson et al. Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
CL2021001488A1 (es) Transposasa de piggybac mutada
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
MX2023014719A (es) Esteroide neuroactivo para el tratamiento de la enfermedad de alzheimer.
BR112022025229A2 (pt) Terapias de anticorpos para infecção por sars-cov-2
UY39061A (es) Inhibidores macrocíclicos de rip2-cinasa
MX2024010708A (es) Composiciones de acido poliglutamico y metodos para usarlas.
MX2021015403A (es) Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario.